AV
ALNY icon

ASR Vermogensbeheer’s Alnylam Pharmaceuticals ALNY Stock Holding History

ASR Vermogensbeheer’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Sell
5,375
-5,848
-52% -$1.76M 0.02% 378
2026
Q1 		$3.71M Buy
11,223
+201
+2% +$68.4K 0.04% 287
2025
Q4 		$4.38M Buy
11,022
+2,146
+24% +$950K 0.05% 270
2025
Q3 		$4.05M Sell
8,876
-50
-0.6% -$20.4K 0.05% 287
2025
Q2 		$2.91M Buy
8,926
+163
+2% +$45.1K 0.04% 316
2025
Q1 		$2.37M Buy
+8,763
New +$2.25M 0.04% 313

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ASR Vermogensbeheer's ALNY Position: Q2 2026 in Review

ASR Vermogensbeheer reduced its Alnylam Pharmaceuticals (ALNY) stake by 52% in Q2 2026, selling an estimated $1.76M and leaving 5,375 shares worth $1.62M. The position accounts for 0.02% of the portfolio, ranked #378.

ASR Vermogensbeheer first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.38M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • ASR Vermogensbeheer held 5,375 shares of Alnylam Pharmaceuticals worth $1.62M as of Q2 2026.
  • ASR Vermogensbeheer sold 5,848 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.76M.
  • Alnylam Pharmaceuticals made up 0.02% of ASR Vermogensbeheer's portfolio in Q2 2026, its #378 holding.
  • ASR Vermogensbeheer first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • ASR Vermogensbeheer's Alnylam Pharmaceuticals position peaked at $4.38M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on ASR Vermogensbeheer's 13F filing for Q2 2026, filed 20 Jul 2026.